Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events

Read full text Summarise with VIRAT
Authors: Jana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, Joanna Mangana, Deniz Özistanbullu, Johannes Kleemann, Alexander H. Enk, Jessica C. Hassel
Cited by: 0
References: 25

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Programmed cell death protein (ligand) 1 (PD-(L)1) inhibitors are well established in the treatment of dermatological tumors. Mostly, they are well tolerated, but in about 9-21% of patients, grade 3/4 immune-related adverse events (irAEs) occur. As treatment options are limited, it is of interest to determine whether readministration of another or the same PD-(L)1 inhibitor is safe. METHODS: This is a multicenter, retrospective study on patients with metastasized dermatological tumors who were retreated with either the same or a different PD-(L)1 inhibitor after the development of irAEs. The study was conducted at centers in Heidelberg, Zurich, and Frankfurt. RESULTS: 22 patients were included between April 2020 and December 2022 with a median age of 71 years. A total of 13 (59%) patients were re-exposed with the same antibody and nine (41%) received a different PD-(L)1 inhibitor. Six (46%) of the patients who were re-exposed to the same antibody had an irAE, of which 67% were identical with the first. In patients receiving a different PD-(L)1 inhibitor, four (44%) developed an irAE, of which 75% were identical with the first. CONCLUSIONS: Both an intraclass switch of PD-(L)1 inhibitor treatment and re-exposure with the same antibody after an irAE can be considered as options with a fair chance of improving therapy tolerance.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Nonmelanoma Skin Cancer Studies Cutaneous Melanoma Detection and Management

Publication details

Journal / source
Current Oncology
Volume
33
Issue
4
Pages
180–180
Publication date
24 March 2026
Language
EN